CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses

• Published in: Vaccine Vol. 37; no. 36; pp. 5382 - 5389
• Main Authors: Tateishi, Koichiro, Fujihashi, Kohtaro, Yamamoto, Norio, Hasegawa, Hideki, Ainai, Akira, Sato, Kayoko, Iho, Sumiko, Yamamoto, Saburo, Maeyama, Jun-ichi, Odagiri, Takato, Asanuma, Hideki
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 23.08.2019; Elsevier Limited
• Subjects: Adjuvant; Adjuvants; Allergy and Immunology; antibodies; Antigens; blood serum; Combined vaccines; CpG islands; CpG ODN G9.1; Experiments; Gene expression; IgA; IgG antibody; Immune response; Immune system; Immunoglobulin A; Immunoglobulin G; Infections; Infectious diseases; Inflammation; Influenza; influenza vaccines; Interferon; Lungs; mice; Mucosa; Nasal vaccination; nose; oligodeoxyribonucleotides; Oligonucleotides; Orthomyxoviridae; R&D; Research & development; Respiratory tract; vaccination; Vaccines; Viruses; United States > US; Japan; California; IgA; SRD; Nasal vaccination; PBMC; LD50; BSA; SD; Influenza; ODN; CpG ODN G9.1; Adjuvant; SEM; pfu; single radial immunodiffusion; plaque forming unit; LD 50; standard error of the mean; oligodeoxynucleotide; median lethal dose; peripheral blood mononuclear cell; bovine serum albumin; standard deviation

This study examined the protective efficacy of and immune response to a nasal influenza vaccine combined with a novel mucosal oligodeoxynucleotide (ODN) adjuvant, CpG ODN G9.1 (G9.1), in a model of infection limited to the upper respiratory tract (URT) and a model of infection in the lower respirato...